Immunovant Inc (IMVT)
$28.57
+0.77
(+2.77%)▲
Live
Performance
- $28.08$29.01$28.57
1.72%
Downside
Day's Volatility :3.21%
Upside
1.52%
- $18.82$45.58$28.57
34.13%
Downside
52 Weeks Volatility :58.71%
Upside
37.32%
Returns
| Period | Immunovant Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 2.32% | 6.5% | 0.0% |
6 Months | -27.32% | 7.1% | 0.0% |
1 Year | 29.3% | 9.8% | 0.0% |
3 Years | 172.55% | 14.2% | -20.2% |
Highlights
Market Capitalization | 4.1B |
Book Value | $4.24 |
Earnings Per Share (EPS) | -1.88 |
Wall Street Target Price | 49.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.5% |
Return On Equity TTM | -52.91% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -270.0M |
Diluted Eps TTM | -1.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.77 |
EPS Estimate Next Year | -1.86 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.45 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 71.51%
Technicals Summary
Sell
Neutral
Buy
Immunovant Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Immunovant Inc | 6.68% | -27.32% | 29.3% | 172.55% | 183.67% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Immunovant Inc | NA | NA | NA | -1.77 | -0.53 | -0.31 | NA | 4.24 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Immunovant Inc | Buy | $4.1B | 183.67% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Immunovant Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 32.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 14.0%
Institutional Holdings
FMR Inc
5.24%Vanguard Group Inc
4.44%BlackRock Inc
3.07%State Street Corporation
2.49%Perceptive Advisors LLC
2.03%Armistice Capital, LLC
1.48%
Corporate Announcements
Immunovant Inc Earnings
Immunovant Inc’s price-to-earnings ratio stands at None
Read More
Company Information
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Organization | Immunovant Inc |
Employees | 207 |
CEO | Dr. Frank M. Torti M.B.A., M.D. |
Industry | Finance |
